Glenmark Launches Epinephrine Injection in US Targeting $42.7 Million Market

Glenmark Pharmaceuticals has officially launched its generic version of Epinephrine injection in the United States, a significant move that positions the company to capitalize on a market valued at approximately $42.7 million. The newly introduced 10 mg/10 mL (1 mg/mL) multiple-dose vial is bioequivalent and therapeutically equivalent to the reference drug from BPI Labs, LLC.

This launch is crucial as it qualifies for 180 days of competitive generic therapy (CGT) exclusivity, providing Glenmark a strategic advantage in the market. The Epinephrine injection is primarily used to treat hypotension associated with septic shock and for emergency responses to allergic reactions.

Marc Kikuchi, President and Business Head for North America at Glenmark, emphasized that this launch enhances the company's institutional product portfolio while reinforcing their commitment to offering quality and affordable healthcare alternatives.

With this introduction, Glenmark continues to strengthen its presence in the U.S. pharmaceutical market, responding to increasing demand for effective and accessible treatment options. The launch not only marks a milestone for Glenmark but also contributes to the broader goal of improving patient care through affordable medication.